- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novocure Ltd (NVCR)
Novocure Ltd stock price live, this page displays NASDAQ NVCR stock exchange data. View the NVCR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Novocure Ltd real time stock price chart below.
What Is the Novocure Ltd Stock Price Today?
The Novocure Ltd stock price today is 17.13.
What Is the Stock Symbol for Novocure Ltd?
The stock symbol for Novocure Ltd is "NVCR."
What Stock Exchange Does Novocure Ltd Trade On?
Novocure Ltd is listed and trades on the NASDAQ stock exchange.
Is Novocure Ltd a Good Stock to Buy?
Determining whether Novocure Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVCR quote. (ISIN: JE00BYSS4X48)
What Is the Novocure Ltd Stock Price Today?
The Novocure Ltd stock price today is 17.13.
What Is the Stock Symbol for Novocure Ltd?
The stock symbol for Novocure Ltd is "NVCR."
What Stock Exchange Does Novocure Ltd Trade On?
Novocure Ltd is listed and trades on the NASDAQ stock exchange.
Is Novocure Ltd a Good Stock to Buy?
Determining whether Novocure Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVCR quote. (ISIN: JE00BYSS4X48)
Currency in USD
17.13
-0.52(-2.95%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.13
18.15
52 wk Range
9.82
21.45
NVCR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.1318.15
52 wk Range
9.8221.45
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVCR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
27.14
Upside
+58.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Novocure Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Novocure Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Novocure Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Form 144 NovoCure Limited For: 24 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Analyst Ratings
4 Buy
3 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 27.14
(+58.45% Upside)
Novocure Ltd SWOT Analysis
Innovative Cancer Tech | Novocure's Tumor Treating Fields therapy revolutionizes oncology, with promising applications beyond glioblastoma multiforme treatment |
Market Expansion | Explore Novocure's strategic growth in Europe, particularly France, and potential opportunities in Italy and Spain's healthcare markets |
Financial Performance | Analysts project 16.7% revenue growth for 2024, with price targets ranging from $24 to $40, despite current operational losses |
Future Prospects | Delve into Novocure's product pipeline, including new arrays for lung cancer and anticipated FDA approvals, shaping its competitive edge |
Novocure Ltd Earnings Call Summary for Q2/2026
- NovoCure Q2 revenue rose 16% YoY to $183.6M, beating estimates by $10.9M; loss narrowed to 13¢/share vs 33¢ expected; shares surged 15.61%
- Adjusted EBITDA turned positive at $11M vs negative $10M year-ago; gross margin expanded 400bps to 78% driven by manufacturing efficiencies
- Full-year 2026 revenue guidance raised to $710M-$725M from $690M-$710M; adjusted EBITDA outlook set at $0-$15M, targeting breakeven
- Strategic shift announced from developing new cancer applications to strengthening existing approved indications and broadening product labels
- Optune Pax and Lua launches progressing; Optune Maia FDA decision expected Q4 2026; combined new product revenue forecast at $20M-$30M for year
Last Updated: 2026-07-23, 09:02 a/m
Read Full TranscriptEarnings
Latest Release
Jul 23, 2026
EPS / Forecast
-0.13 / -0.33
Revenue / Forecast
183.6M / 172.72M
Compare NVCR to Peers and Sector
Metrics to compare | NVCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVCRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.6x | −2.6x | −0.4x | |
PEG Ratio | −0.84 | −0.20 | 0.00 | |
Price/Book | 6.0x | 3.5x | 2.6x | |
Price / LTM Sales | 2.9x | 3.0x | 2.9x | |
Upside (Analyst Target) | 44.3% | 95.8% | 58.0% | |
Fair Value Upside | Unlock | 23.1% | 9.5% | Unlock |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Novocure Ltd (NVCR) Stock Price Today?
The Novocure Ltd stock price today is 17.13 USD.
What Stock Exchange Does Novocure Ltd Trade On?
Novocure Ltd is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Novocure Ltd?
The stock symbol for Novocure Ltd is "NVCR."
What Is the Novocure Ltd Market Cap?
As of today, Novocure Ltd market cap is 2.03B USD.
What Is Novocure Ltd's Earnings Per Share (TTM)?
The Novocure Ltd EPS (TTM) is -1.31.
When Is the Next Novocure Ltd Earnings Date?
Novocure Ltd will release its next earnings report on Oct 22, 2026.
From a Technical Analysis Perspective, Is NVCR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Novocure Ltd Stock Split?
Novocure Ltd has split 0 times.
How Many Employees Does Novocure Ltd Have?
Novocure Ltd has 1605 employees.
What is the current trading status of Novocure Ltd (NVCR)?
As of Jul 27, 2026, Novocure Ltd (NVCR) is trading at a price of 17.13 USD, with a previous close of 17.65 USD. The stock has fluctuated within a day range of 17.13 USD to 18.15 USD, while its 52-week range spans from 9.82 USD to 21.45 USD.
What Is Novocure Ltd (NVCR) Price Target According to Analysts?
The average 12-month price target for Novocure Ltd is 27.14 USD, with a high estimate of 52 USD and a low estimate of 17 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +58.45% Upside potential.
What Is the NVCR Premarket Price?
NVCR's last pre-market stock price is 17.92 USD. The pre-market share volume is 13,600.00, and the stock has decreased by 0.27, or 1.53%.
What Is the NVCR After Hours Price?
NVCR's last after hours stock price is 17.60 USD, the stock has decreased by -0.05, or -0.28%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.